|
Elena's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: EpiVax adds AI immunogenicity models, K2 Therapeutics seeks $250 million, and Rigel bets on Pfizer-licensed Veppanu for growth.
The top 10 stories from Wed Sep 2, 2026 06:49 AM to Thu Sep 3, 2026 06:49 AM
Generated September 3, 2026 at 6:49 AM
|
|
|
#1 EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction Published 2026-09-02 EpiVax released AI-enabled enhancements to its ISPRI platform, including an updated JanusMatrix model for assessing biotherapeutic immunogenicity risk. Covered by: prnewswire.com, prnewswire.com |
#2 Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain Published 2026-09-03 Insilico Medicine announced its inclusion in the HKEX Tech 100 Index following methodology enhancements. Covered by: prnewswire.com |
#3 FDA leaders project enhanced scrutiny of foreign data Published 2026-09-02 FDA leaders are strengthening oversight of foreign clinical-trial data, amid concerns from lawmakers and industry about China’s expanding role in drug research. Covered by: endpoints.news, biospace.com |
#4 K2 Therapeutics: Spreading bets across range of Asia-sourced assets Published 2026-09-03 K2 Therapeutics, led by former Legend CEO Ying Huang, is seeking a $250 million Series A to develop a diversified portfolio of Asia-sourced assets. Covered by: biocentury.com |
#5 STAT+: How a former ARPA-H director’s startup is tackling AI’s ‘dumb problems’ Published 2026-09-02 STAT+ profiles a startup founded by a former ARPA-H director that aims to address basic operational challenges limiting artificial intelligence in health care. Covered by: statnews.com |
#6 Japan Health Ministry Eyes AI Investment For Pharma Innovation, Regulation Published 2026-09-02 Japan’s health ministry budget request includes AI projects for drug discovery, molecular design, and regulatory reviews of pharmaceutical products. Covered by: insights.citeline.com |
#7 BC Platforms launches BC Mosaic App Store to empower data scientists and healthcare researchers with innovative analytics and workflow applications Published 2026-09-02 BC Platforms announced the BC Mosaic App Store, integrating certified analytics and workflow applications into its trusted research environment for healthcare and life sciences teams. Covered by: prnewswire.com |
#8 Rigel All In On New Growth Driver, Veppanu, Licensed From Pfizer Published 2026-09-02 Rigel CEO Raul Rodriguez discussed licensing Pfizer’s breast cancer drug Veppanu, which Rigel expects to become its largest-selling product despite limited revenue potential for Pfizer. Covered by: insights.citeline.com |
#9 Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies Published 2026-09-02 Typewriter raised $56 million to develop jumping-gene technology for delivering full genes in humans and creating in vivo CAR-T therapies without viral vectors. Covered by: endpoints.news |
#10 Celiac Data Support Teva’s IL-15 Antagonist As A Potential ‘Pipeline-In-A-Product’ Published 2026-09-02 Teva’s IL-15 antagonist has generated celiac disease data supporting its potential as a broad pipeline asset, though it has not yet reached the market. Covered by: insights.citeline.com |
